EMA Decides Fast-Track Fate Of Masitinib And Anthrax Antitoxin
Executive Summary
The European Medicines Agency is this week deciding whether it will fast track its review of orphan drugs from two companies, one of which has previously tried but failed to get the same product approved for sale in the EU.
You may also be interested in...
EU Accelerated Assessment Tracker
Accelerated assessment requests at the European Medicines Agency.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.